Highest development stage: Phase 1 for human use (as of 2022)

Development status: Approved for veterinary use, off-patent

Gram-negative activity

Mechanism of Action/Target pathogen: Inhibits protein synthesis by binding to the 30S subunit of the bacterial ribosome. Active against Gram-negative bacteria

Additional information: Streptomyces natural product. Veterinary use, redeveloped for human use